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Abstract
Background Vascular complications in homocystinuria have
been known for many years, but there have been no reports to
date on involvement of the ascending aorta.
Methods We conducted a cross-sectional study of patients
with homocystinuria, known to a single metabolic centre,
and evaluated in 2016 with a transthoracic echocardiogram.
Aortic root dilation was defined as Z-score ≥ 2.0 SD, and
graded mild (Z-score 2.0–3.0), moderate (Z-score 3.01–4.0)
and severe (Z-score > 4.0).
Results The study population included 34 patients, median
age of 44.3 years (IQR 33.3–52.2), 50% males, 69% diag-
nosed aged <18 years and 29% pyridoxine-responsive. Eight
(24%) had a history of hypertension. Seven patients (21%)
were found to have a dilation of the aortic root, mild in two
cases (6%), moderate in four (12%) and severe in one (3%).
None had dilation of the ascending aorta. Significant aortic
regurgitation, secondary to moderate aortic root dilation, was
documented in two patients. A single patient had significant
mitral regurgitation due to prolapse of both valve leaflets, as
well as mild aortic root dilation. Comparing patients with a
dilation of the aortic root to those without, there were no
significant clinical, laboratory or echocardiographic differ-
ences, with the only exception being that the diameter of the
ascending aorta was larger in the group with a dilated aortic
root, albeit within normal limits.
Conclusions A subset of patients with homocystinuria have
isolated dilation of the aortic root similar to that observed in
Marfan syndrome.
Introduction
Homocystinuria (HCU, OMIM 236200) is a rare autosomal
recessive genetic disease caused by cystathionine β-synthase
Communicated by: William Ross Wilcox
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10545-017-0094-7) contains supplementary
material, which is available to authorized users.
* Elaine Murphy
elaine.murphy8@nhs.net
1 University College London Institute for Cardiovascular Science and
Barts Heart Centre, St. Bartholomew’s Hospital, London, UK
2 Cardiology, Department of Experimental, Diagnostic and Specialty
Medicine, Alma Mater Studiorum University of Bologna,
Bologna, Italy
3 Department of Clinical Biochemistry, John Radcliffe Hospital and
Nuffield Division of Clinical Laboratory Sciences, University of
Oxford, Oxford, UK
4 Metabolic Medicine, Great Ormond Street Hospital for Children
NHS Foundation Trust, London, UK
5 Division of Cardiovascular Medicine, Radcliffe Department of
Medicine, University of Oxford, Oxford, UK
6 Adult Congenital Heart Disease Department, Barts Heart Centre, St.
Bartholomew’s Hospital, London, UK
7 Department of Clinical Biochemistry, North Bristol NHS Trust,
Bristol, UK
8 Charles Dent Metabolic Unit, National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK
J Inherit Metab Dis
DOI 10.1007/s10545-017-0094-7
(CBS, EC 4.2.1.22) deficiency (Mudd 2011). The phenotype
is variable and can include: Marfanoid appearance, mental
retardation, epilepsy, vascular complications, ectopia lentis
and osteoporosis (Mudd et al. 2001). Based mainly on geno-
type (Mudd et al. 2001), a subset of patients respond to pyri-
doxine (vitamin B6), these patients tend to present later, and
with a milder phenotype (Mudd et al. 1985). Treatment for
non-pyridoxine responsive patients includes a combination of
a restricted protein diet, methionine-free amino acid supple-
mentation, vitamin B12, folate and betaine.
Thromboembolic disease is a major cause of morbidity and
mortality in HCU. In an untreated cohort of HCU patients,
50% experienced a thromboembolic event by the age of 30
and thromboembolism was reported as a significant factor in
80% of deaths (Mudd et al. 1985). Accelerated atherosclerosis
is also known to be associated with HCU (Mudd et al. 1985;
Yap et al. 2001; McCully 2015). No clinical trials have inves-
tigated the issue, but observational studies (Wilcken and
Wilcken 1997; Yap et al. 2000, 2001) have described a lower
incidence of vascular complications in treated patients com-
pared to the expected rates derived from a historical untreated
cohort (Mudd et al. 1985).
Following the incidental documentation of aortic root dila-
tion in a patient with HCU, patients at our centre were sys-
tematically screened with an echocardiogram in order to in-
vestigate the prevalence of dilation of the ascending aorta in
this population.
Methods
We conducted a cross-sectional study of patients with HCU
known to the Charles Dent Metabolic Unit of the National
Hospital for Neurology and Neurosurgery, London (N = 32),
the John Radcliffe Hospital, Oxford (N = 1) and Southmead
Hospital, Bristol (N = 1) who underwent a transthoracic echo-
cardiogram in 2016. The biochemical diagnosis of HCU was
based on plasma total homocysteine (Hcy) levels, according to
the current recommendations (Morris et al. 2016) and patients
were not routinely genotyped. Plasma hypermethioninemia
(>45 μmol/L) was documented in 30 of the 34 patients.
Cystathionine was not routinely measured. Of the remaining
four patients, methionine levels were either ≤45 μmol/L or
could not be traced. All four of these patients were clearly
documented to be responsive to pyridoxine. As universal new-
born screening for HCU only commenced in the UK in 2015,
all of these adult patients were either diagnosed following
clinical presentation or as part of a family screen following
diagnosis in an index sibling. Clinical details were obtained
from electronic records. Pyridoxine-responsiveness was deter-
mined at diagnosis and was defined as a sustained reduction of
plasma total Hcy to <75 μmol/L following treatment with
pyridoxine, with normal folate and B12 levels, and without
the need for betaine or dietary modification. As part of routine
clinical follow up patients also underwent bone mineral den-
sitometry. Reduced bone mineral density was defined as Z-
score < −2.0 or T-score < −1.0.
Aortic root dimension was obtained in the parasternal long
axis view, measuring the maximal diameter at the sinuses of
Valsalva, according to the current recommendations (Lang et al.
2015). The predicted aortic root diameter was calculated con-
sidering age, gender and body surface area (BSA, calculated
using the Dubois formula), according to Devereux et al. (2012)
by using the following formula: 2.423 + (age [years] * 0.009) +
(BSA [squaremeters] * 0.461) + (gender [1 =man, 2 =woman]
* 0.267). Z-score was calculated using SD 0.261 cm. Aortic
dilation was defined as Z-score ≥ 2.0 SD, and graded mild (Z-
score 2.0–3.0), moderate (Z-score 3.01–4.0) and severe (Z-
score > 4.0). The ascending aorta, valvular disease and left
ventricular ejection fraction were evaluated according to current
guidelines (Lancellotti et al. 2013; Lang et al. 2015).
Cumulative Hcy exposure was calculated as follows: (age
at diagnosis * Hcy at diagnosis) + [(age at last follow up – age
at diagnosis) * mean Hcy during follow up].
Statistical analysis
Continuous variables are reported as median (interquartile
range), categorical values as number (percentage).
Continuous variables were compared using Mann-Whitney
test and categorical variables compared using Fisher’s exact
test. The relationship between cumulative Hcy exposure and
Z-score was assessed using Spearman’s rank-order correla-
tion. A p-value <0.05 was considered significant. Statistical
analyses were carried out using IBM SPSS Statistics for
Windows, version 24.0 (IBM Corp., Armonk, N.Y., USA).
Results
The study population consisted of 34 patients, with a median
age of 44.3 years (IQR 33.3–52.2), 50% of them males.
Seventy percent of patients had been diagnosed before the
age of 18, and 29% were pyridoxine-responsive. Patients
who were not pyridoxine-responsive were advised not to con-
sume excessive protein, but as a restricted protein diet is dif-
ficult to initiate and sustain in older patients, only four patients
followed a formal prescribed low protein diet with specific
HCU-appropriate amino acid supplementation. Twenty-
seven (79%) had at least one of the known complications of
HCU, the most frequent being lens dislocation (present in
62%). Vascular complications were venous in all cases, no
patient had a history of arterial thrombosis. Eight patients
(24%) had a history of hypertension. Clinical, laboratory and
echocardiogram findings of the overall population are report-
ed in Table 1. Seven patients (21%) were found to have a
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dilation of the aortic root, this was mild in two cases (6%),
moderate in four (12%) and severe in one (3%) (Table 2). The
ascending aorta was within normal limits in all cases.
Significant (≥ moderate) aortic regurgitation, secondary to
moderate aortic root dilation, was documented in two patients.
Significant mitral regurgitation due to prolapse of both valve
leaflets was found in a single patient who also had mild aortic
root dilation. All patients were found to have a non-dilated left
ventricle with a normal ejection fraction. Against medical ad-
vice, the patient with severe aortic root dilation exercised reg-
ularly in the gym, focusing mainly on weight lifting and took
protein powder supplements with the aim of increasing
muscle mass. The concern in this case was that he might also
have a second underlying contributing genetic condition.
Sequencing of his genomic DNA against a panel of 20 genes
associated with familial thoracic aortic aneurysms identified
only heterozygous previously described known pathogenic
CBS mutations (c.[667-14_667-7del(;)1566del]). This gene
panel included the ACTA2, COL3A1, FBN1, FBN2, FLNA,
GATA5, MFAP5, MYH11, MYLK, NOTCH1, PRKG1, SKI,
SLC2A10, SMAD3, SMAD4, TGFB2, TGFB3, TGFBR1 and
TGFBR2 genes. Of the four patients with moderate aortic root
dilation, two lifted weights regularly in the gym and one of the
two also took protein powder supplements.









Age, years (IQR) 44.3 (33.3–52.2) 44.4 (33.0–50.6) 40.9 (33.5–57.5) 0.739
Male, n (%) 17 (50%) 12 (44%) 5 (71%) 0.398
Caucasian, n (%) 24 (71%) 19 (70%) 5 (71%) 1.000
Age < 18 years at diagnosis, n (%) 20/29 (69%) 16/22 (73%) 4/7 (57%) 0.642
Pyridoxine-responsive, n (%) 10 (29%) 8 (30%) 2 (29%) 1.000
Total Hcy, μmol/L (IQR) 96.5 (66.4–117.4) 95.7 (60.7–116.7) 98.7 (72.0–119.7) 0.934
Treatment: Folate 34 (100%) 27 (100%) 7 (100%) 1.000
B12 33 (97%) 27 (100%) 6 (86%) 0.206
Pyridoxine 32 (94%) 26 (96%) 6 (86%) 0.374
Betaine 22 (65%) 18 (67%) 4 (57%) 0.677
Low protein diet 4 (12%) 3 (11%) 1 (14%) 1.000
Number of complications: 0 7 (21%) 6 (22%) 1 (14%)
1 9 (27%) 6 (22%) 3 (43%)
2 14 (41%) 12 (44%) 2 (29%) 0.901
3 3 (9%) 2 (7%) 1 (14%)
4 1 (3%) 1 (4%) 0
Lens dislocation, n (%) 21 (62%) 15 (56%) 6 (86%) 0.210
Venous thrombosis, n (%) 5 (15%) 4 (15%) 1 (14%) 1.000
Intellectual impairment, n (%) 5 (15%) 4 (15%) 1 (14%) 1.000
Epilepsy, n (%) 2 (6%) 2 (7%) 0 1.000
Reduced BMD, n (%) 16/28 (57%) 14/24 (58%) 2/4 (50%) 1.000
Pancreatitis, n (%) 2 (6%) 1 (4%) 1 (14%) 0.374
History of hypertension, n (%) 8 (24%) 6 (22%) 2 (29%) 1.000
Systolic BP, mmHg (IQR) 124 (115–135) 125 (115–135) 122 (116–145) 0.478
Diastolic BP, mmHg (IQR) 80 (75–80) 80 (75–80) 76 (72–88) 0.452
Aortic root, mm (IQR) 33.5 (28.8–39) 32 (28–36) 43 (39–46) <0.001
Indexed aortic root, mm/m2 (IQR) 18.9 (16.8–20.7) 17.2 (15.6–19.3) 21.6 (20.2–23.9) <0.001
Indexed ascending aorta, mm/m2 (IQR) 16.8 (15.3–17.7) 15.6 (15.0–17.2) 18.1 (17.2–20.8) 0.007
Aortic regurgitation >2+, n (%) 2 (6%) 0 2 (29%) 0.370
Mitral regurgitation >2+, n (%) 1 (3%) 0 1 (14.3%) 0.206
Left ventricular EF, % (IQR) 60 (60–64) 60 (60–64) 60 (59.3–67.3) 0.869
The complications considered were: lens dislocation, venous or arterial thrombosis, intellectual impairment, epilepsy, reduced BMD and pancreatitis
Hcy homocysteine, BMD bone mineral density, BP blood pressure, EF ejection fraction
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When comparing patients with dilation of the aortic root to
those without, there were no significant clinical, laboratory or
echocardiographic differences, with the only exception being
that the diameter of the ascending aorta was larger in the group
with a dilated aortic root, albeit still within normal limits
(Table 1). In the subset of patients with complete available
data (n = 12), no correlation was found between cumulative
Hcy exposure and aortic root Z-score (rs − 0.007, p = 0.983;
Fig. 1).
Discussion
This is the first study to describe the relatively high prev-
alence of isolated aortic root dilation in HCU, that affects
one in five patients, and does not appear to be associated
with any of the main demographic, clinical or laboratory
findings.
The isolated aortic root dilation we observed in our cohort
is similar to that seen in Marfan syndrome (MFS, OMIM
154700), a disease caused in most cases by mutations in the
FBN1 gene, that encodes fibrillin-1, but to a lesser degree. By
forming a lattice around elastic fibres, fibrillin-1 plays an im-
portant structural role in the extracellular matrix. However,
haploinsufficiency leading to a weakening of connective tis-
sue does not explain all components of the MFS phenotype,
such as long bones (Cañadas et al. 2010). Fibrillin-1 also plays
a complex and not completely understood role, interacting
with vascular smooth muscle cells and regulating growth fac-
tor activity, particularly of TGF-β1. The increased availability
of TGF-β1 caused by mutated fibrillin-1 protein leads to ma-
trix metalloproteinase expression and thereby matrix degrada-
tion and inflammation (El-Hamamsy and Yacoub 2009).
Experimental models have shown that elevated Hcy levels,
compatible with those of patients with HCU, can lead to re-
duction of the disulfide bonds in fibrillin-1 leading to a loss of
structure (Hutchinson et al. 2005), and hence to increased
TGF-β1 activity (El-Hamamsy and Yacoub 2009). This sug-
gests a pathophysiology partially shared by the two diseases,
that would explain the common phenotypic traits, with the
lower frequency of aortic disease observed in HCU being
due to the different mechanism of fibrillin-1 degeneration,
i.e. acquired from exposure to high levels of circulating Hcy
rather than from congenital mutation of the protein. The char-
acteristic isolated dilation of the aortic root in MFS is believed
to be due to the higher elastic fibre content (containing
fibrillin-1) in the aortic root, combined with the wall stress
and cyclic torsion to which it is subjected (Cañadas et al.
2010) and it can be speculated that the same principles apply
in HCU.
However, while MFS is known to be an important cause of
aortic dissection, particularly in young patients, with a preva-
lence reaching 5% in large dissection registries (Januzzi et al.
2004; Vagnarelli et al. 2015), to the best of our knowledge, to
date there have been no reports of aortic dissection in HCU.
There have been reports of carotid artery (Kelly et al. 2003;
Weiss et al. 2006) or coronary dissection (Granel et al. 2009),









Regular (> twice per week)
isometric exercise in the gym
Taking a non-prescribed
protein supplement
1 38 No No 120/70 F, B12, P, B 39 No No
2 51 No Yes 135/85 F, B12, P, B 39 No No
3 33 No No 122/72 F, B12, P 43 Yes Yes
4 41 No No 145/90 F, B12, P, B 43 Yes No
5 63 Yes Yes 160/80 F, B12, P 46 No No
6 57 Yes No 116/76 F, B12, P 41 No No
7 26 No No 115/75 F, B, Diet 50 Yes Yes
F folate, B12 vitamin B12, P pyridoxine, B betaine, Diet prescribed low protein diet
Fig. 1 The relationship of aortic root dimensions to lifetime
homocysteine exposure. In the subset of patients with available data, no
correlation was found between cumulative Hcy exposure [age at
diagnosis * Hcy at diagnosis] + [(age at last follow up - age at diagnosis)
* mean Hcy during follow up] and aortic root Z-score (rs − 0.007,
p = 0.983). A Z-score > 2 indicates aortic root dilation
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as well as two cases of abdominal aortic aneurysm (Yap et al.
2001), but considering the localization of these vascular com-
plications, they possibly had a different, atherosclerotic path-
ogenesis. Whilst it is possible that the risk of dissection sec-
ondary to aortic root dilation is lower in patients with HCU
than with MFS, it may be that the lack of reports to date
simply reflects the fact that HCU is a rare disease, potentially
underdiagnosed when it does not express the classic pheno-
type, particularly in adults presenting with isolated vascular
complications and no other phenotypic features (Brenton
1977; Gaustadnes et al. 2000; Kelly et al. 2003; Linnebank
et al. 2003). As aortic root dilation affects only a subset of
patients, the absolute number of HCU patients who experi-
ence an aortic dissection can be expected to be extremely
low. Most patients with dissections secondary to MFS present
in their 4th to 5th decade (Januzzi et al. 2004) and so many
surviving adult patients with HCU may still be too young to
experience this complication. The introduction of newborn
screening and earlier treatment aims to lower lifetime Hcy
exposure, altering the natural history of the condition and
ultimately potentially reducing the risk of aortic root dilation
and dissection. To date no studies have reported systematic
screening of patients with aortic dissection for HCU, although
the CBS gene is currently included in various aortopathy gene
panels.
The fact that amongst the five patients with moderate or
severe aortic root dilation in our series, three regularly lifted
weights and two also took protein powder supplements is in
line with our pathophysiological hypothesis. Despite the fact
that extreme blood pressure values (exceeding 480/
350 mmHg) have been recorded by indwelling catheter during
weight lifting (MacDougall et al. 1985), the association be-
tween isometric exercise and aortic root dilation in athletes
remains unclear (Pelliccia et al. 2012). Nevertheless, aortic
rupture is a known, albeit rare, cause of sudden death in ath-
letes and was found to be responsible for 2% of cardiovascular
deaths in a large US registry (Maron et al. 2009), although it is
not known whether these athletes had an undiagnosed
aortopathy. Despite the lack of specific outcome data, all cur-
rent guidelines are extremely restrictive regarding sports par-
ticipation in patients with MFS or other genetic aortopathies
(Pelliccia et al. 2005; Braverman et al. 2015), and based on
our findings it is reasonable to advise patients with HCU
against strenuous exercise, particularly if isometric.
The fact that no correlation was found between cumulative
Hcy exposure and aortic root Z-score does not invalidate our
pathophysiological hypothesis. The result can be explained by
the small size of the subgroup analysis and possibly by the
contribution of weight-lifting to the development of aortic root
dilation in this population.
Two of the patients with aortic root dilation in this series
had a history of hypertension and, despite the fact that ambu-
latory blood pressure values were satisfactory, this could be
considered a confounder. The prevalence of a history of hy-
pertension however, did not differ significantly between the
two groups, and the relationship between hypertension and
aortic root dilation, remains controversial despite the large
number of studies that have investigated the issue (Mulè
et al. 2016). The main determinants of aortic root size are
known to be age, gender and body size, all are considered in
the Z-score formula proposed by Devereux et al. that was used
in this study. Compared to the previous, longstanding nomo-
grams, this formula has been found to perform better in pa-
tients with MFS (van Kimmenade et al. 2013), as previous
methods did not consider age and gender, as well as being
derived from a much smaller cohort (Roman et al. 1989).
Our observations require confirmation in larger,
multicentre cohorts. However, considering the improved life
expectancy of patients with HCUwith contemporary manage-
ment, that aortic dissection secondary to aortic root dilation is
a potentially preventable life-threatening complication, and
that dimensions of the proximal aorta can be cheaply and
non-invasively assessed with a transthoracic echocardiogram,
all patients should be offered screening for aortic root dilation.
Losartan inhibits TGF-β mediated activation of extracellular
metalloproteinase (Habashi et al. 2006) and is widely used in
MFS having been shown to slow aortic root dilation compared
to beta-blockers or placebo, even though it does not seem to
reduce adverse clinical events (Gao et al. 2016). Based on our
pathophysiological hypothesis, Losartan should be strongly
considered as treatment in patients with HCU and hyperten-
sion, but further evidence is required before it can be routinely
recommended in patients with HCU, aortic root dilation and
normal blood pressure. Currently, in our unit, those patients
with a dilated aortic root at baseline are followed as deemed
clinically appropriate by the cardiac team. Those patients with
a normal aortic root at baseline are offered a repeat echocar-
diogram every 3 years.
Limitations
A limitation of the present study is the absence of a control
group and our findings should be confirmed and the possible
modifier role of isometric exercise investigated through larger,
case-control studies. Our data on the prevalence of aortic root
dilation cannot be compared directly with available literature
due to the different definitions of ‘aneurysm’. However, the
few available studies suggest that it is a rare condition in the
general population and the prevalence in our cohort was de-
cidedly higher than could be expected. Amongst 6971
Japanese adults undergoing chest CT for lung cancer or tuber-
culosis screening the prevalence of dilation of the ascending
aorta (defined as mean diameter for age + 3SD) was 0.04%
(Itani et al. 2002). In the Heinz Nixdorf Recall study, aortic
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aneurysms ≥5 cm on chest CT were found in 0.34% of 4129
German subjects (Kälsch et al. 2013).
Despite the fact that 70% of our population was diagnosed
in a pediatric context and have undergone medical follow-up
ever since, and that there have been no documented cases of
aortic dissection amongst the patients followed up at our cen-
tre, this cross-sectional study is not able to determine the risk
of aortic dissection in HCU and larger prospective studies will
be required.
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